drugset
drugset / Trial / NCT01306253

A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2009/2010 Influenza Virus Strains for the Northern Hemisphere

NCT01306253 ↗

Phase 4 Completed 114 enrolled Crucell Holland BV
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is to assess whether the Northern Hemisphere 2009/2010 season influenza vaccine Inflexal V fulfills the EMEA requirements for re-registration of influenza vaccines.

Timeline

Start
2009-06
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Inflexal V Vaccine 0.5 ml Intramuscular

Indications

influenza